MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced the presentation of results of a successful pivotal phase 3 trial of Aquavan® (fospropofol disodium) Injection in patients undergoing colonoscopy. Primary and secondary efficacy endpoint results, as well as safety data, were presented at Digestive Disease Week 2007 in Washington, D.C. by Lawrence B. Cohen, MD, Department of Medicine/ Gastroenterology, Mount Sinai School of Medicine, New York.
